Citi initiates Insilico buy/high-risk coverage amid AI drug-creation claims
Citi analysts initiated coverage on Insilico with a buy/high-risk rating, citing sustained preclinical candidate generation since 2021 across multiple therapeutic areas and a test of AI’s expansion of pharma innovation.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.